A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B

Chang, Ting‐Tsung; G. Gish, Robert; de Man, Robert; Gadano, Adrián; D. Sollano, Jose; Chao, You‐Chen; S. Lok, Anna; Han, Kwang‐Hyub; Goodman, Zachary; Liang Zhu, Jin; Cross, Anne; DeHertogh, Deborah; B. Wilber, Richard; J. Colonno, Richard; Apelian, David

doi:10.1056/nejmoa051285

Public

A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B

Published in New England Journal of Medicine • Mar 8, 2006

Authors:

Ting‐Tsung Chang

Robert G. Gish

Robert de Man

Abstract

BACKGROUND: Entecavir is a potent and selective guanosine analogue with significant activity against hepatitis B virus (HBV). METHODS: In this phase 3, double-blind trial, we randomly assigned 715 patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B who had not previously receive...

Subject

Entecavir

Lamivudine

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!